Introduction {#s1}
============

In normo-ovulatory women, testosterone (T) levels ([@DMT038C16]; [@DMT038C99]; [@DMT038C44]; [@DMT038C81]) are reported to vary between 0.42 and 2.94 nmol/l ([@DMT038C44]; [@DMT038C81]). T arises from three sources in the female. Approximately 50--60% is derived from the peripheral conversion of the pro-hormones androstenedione (AD) and dehydroepiandrosterone (DHEA) and its sulphate (DHEA-S), whereas 25% is secreted by the ovary and 25% by the adrenal gland ([@DMT038C65]; [@DMT038C8]; [@DMT038C16]). Around 65--70% of circulating T is bound and inactivated by sex-hormone-binding globulin (SHBG). Most of the remaining 30--35% is bound by albumin and only 0.5--3% represents freely circulating T (free T). Since the binding of T to albumin is rather weak, the free- and albumin-bound T together are defined as the bioavailable T ([@DMT038C26]; [@DMT038C99]).

There is much debate regarding adequate methods for measuring total T as well as free T concentrations ([@DMT038C113]; [@DMT038C62]; [@DMT038C87]; [@DMT038C115]; [@DMT038C44]). The most accurate method to assess total T is liquid chromatography-tandem mass spectrometry (LC-MS/MS) ([@DMT038C88]; [@DMT038C114]), although even with LC-MS/MS assays variation in precision exists ([@DMT038C62]). The 'Princeton Consensus Statement' ([@DMT038C8]) recommends equilibrium dialysis as the 'gold standard' method to measure free T concentrations. These methods, however, are very expensive, labour intensive and not available to the great majority of the laboratories. Because of their ease and low costs, immunoassays \[radioimmunoassay (RIA) and electrochemiluminescence immunoassays (ECLIA)\] are most commonly used in clinical practice; however, they are known for their inaccuracy and variability ([@DMT038C105]; [@DMT038C70]; [@DMT038C38]). In particular, immunoassays are affected by cross-reactivity with other steroids ([@DMT038C69]; [@DMT038C13]) and by high levels of SHBG ([@DMT038C68]; [@DMT038C120]). The accuracy of RIA can be improved by the addition of an extraction step or chromatography ([@DMT038C88]; [@DMT038C38]), but these procedures are time consuming. The very low concentrations of free T in female blood (35--700 pmol/l; [@DMT038C99]) are an additional difficulty in obtaining accurate measurements ([@DMT038C105]; [@DMT038C38]). Therefore, free T is often calculated based on total T, SHBG and albumin concentrations ([@DMT038C98]; [@DMT038C112]). This method has been demonstrated to be a reliable measure for free T concentrations ([@DMT038C85]; [@DMT038C70]).

Combined oral contraceptives (COCs) reduce androgen levels ([@DMT038C32]; [@DMT038C1]; [@DMT038C119]; [@DMT038C4]). In particular, blood levels of T, the most potent circulating androgen in women, decrease by up to 50% ([@DMT038C108]; [@DMT038C21]; [@DMT038C37]). Three possible underlying mechanisms may be held responsible for this effect: (i) Suppression of ovarian androgen synthesis; (ii) increased SHBG levels and (iii) suppression of adrenal androgen synthesis.

To exert their contraceptive effect, COCs suppress the gonadotrophins ([@DMT038C34]; [@DMT038C1]). Low levels of LH result in an inhibition of the LH-dependent synthesis of T by the ovarian theca cells ([@DMT038C99]; [@DMT038C23]). As the suppression of T already occurs before the LH levels drops, it is suggested that the contraceptive steroids may have a direct inhibitory effect on ovarian androgen synthesis ([@DMT038C55]; [@DMT038C52]; [@DMT038C1]).

SHBG is a carrier protein synthesized by the liver. Its synthesis is stimulated by estrogens and inhibited by androgens ([@DMT038C36]; [@DMT038C99]). The estrogenic component of COCs, ethinyl estradiol (EE), induces hepatic SHBG production in a dose-dependent manner, resulting in elevated circulating blood levels of SHBG ([@DMT038C51]; [@DMT038C108]; [@DMT038C43]; [@DMT038C4]). Consequently, more T is bound and inactivated, resulting in lower levels of free T and the free androgen index (which is a measure of bioavailable T, i.e. free and albumin-bound T) ([@DMT038C108]; [@DMT038C21]; [@DMT038C15]; [@DMT038C119]; [@DMT038C4]). This EE-induced increase of SHBG can be counteracted by the progestin-component of COC, as a result of the androgenicity of the progestin. COCs containing a progestin with androgenic activity \[e.g. levonorgestrel (LNG)\] will induce a less pronounced increase in SHBG, whereas progestins with concomitant anti-androgenic activity \[e.g. cyproterone acetate (CPA)\] will lead to higher SHBG levels ([@DMT038C109]; [@DMT038C14]; [@DMT038C41]; [@DMT038C108]; [@DMT038C74]; [@DMT038C4], [@DMT038C5]).

The third mechanism of action causing lower levels of androgens is the inhibitory effect of COCs on adrenal androgen synthesis ([@DMT038C32]; [@DMT038C66]; [@DMT038C17]). Several studies have shown that COCs decrease both DHEA and DHEA-S concentrations in blood ([@DMT038C34]; [@DMT038C31]; [@DMT038C118]; [@DMT038C21], [@DMT038C119]; [@DMT038C4]). The underlying mechanism is not yet established, but it has been suggested that a reduced release of adrenocorticotrophic hormone (ACTH) and increased levels of cortisol during COC use may account for the reduced concentrations of adrenal androgens ([@DMT038C18]; [@DMT038C54]; [@DMT038C17]). Consistent with this, ACTH is known to stimulate adrenal androgen secretion ([@DMT038C86]; [@DMT038C65]).

Overall, little attention has been paid to the suppressive effect of COCs on androgens along with its potential clinical implications. Awareness of the significance of androgens for women is increasing, however, and T deficiency is thought to be associated with a broad range of undesired effects including diminished well-being and quality of life, mood changes (depression, irritation, moodiness), loss of energy, cognitive disturbances, interference with optimal sexual functioning, declining muscle mass and strength and lowering of bone density ([@DMT038C8]; [@DMT038C107]).

Although the effect of COCs on T has been extensively investigated, to our knowledge no systematic review or meta-analysis has been performed previously. This analysis aims to evaluate the effect of COC on levels of total T, free T and SHBG in healthy women. Additional subgroup analyses have been performed to evaluate differences between the various types of COCs (e.g. estrogen dose and type of progestin) and to examine the influence of different assessment methods of total T and free T.

Methods {#s2}
=======

This systematic review and meta-analysis has been conducted and reported according to the Cochrane Handbook for Systematic Reviews of Interventions ([@DMT038C48]) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([@DMT038C64]; [@DMT038C71]). Before the start of the study, the review question and inclusion/exclusion criteria were defined. The strategy of this review was discussed and agreed upon, although an official protocol was not published or registered. The review question was: What is the effect of COC on levels of total T, free T and SHBG in healthy women?

Search strategy {#s2a}
---------------

Studies were identified by searches of the following electronic databases with no restrictions in date of publication (i.e. from inception date until July 2012): MEDLINE, EMBASE and the Cochrane Central Register of Clinical Trials. The search strategy was based on synonyms in title and abstract using the following terms: ('hormonal contracept\*' OR 'contracept\*' AND 'steroids' OR 'contracept\*' AND 'pill') AND ('androgen\*' OR 'testost\*'). In all searches, limits were set for MeSH (humans and female), publication type (clinical trial) and language (English, German or Dutch).

In addition, a 'pearl growing' strategy was employed, whereby, after obtaining the full text articles, the reference lists of all included studies were reviewed for additional publications that could be used in this review.

Selection criteria {#s2b}
------------------

All studies investigating the effect of COCs on androgen levels in healthy women were eligible for selection. At least two of the following three outcome parameters had to be reported: total T, free T and SHBG. Exclusion criteria were studies in men or animals, women suffering from acne, polycystic ovary syndrome, hirsutism or endometriosis, (post)menopausal women, no or other types of hormonal contraception (e.g. progestin-only contraceptives, implants, patches, vaginal rings, intrauterine device), COC with a continuous regimen, emergency contraception, treatment duration of less than one cycle (i.e. one cycle is 28 days), other outcome parameters (e.g. cervical mucus, acne, endometriosis) and bioequivalence/bioavailable studies. Reviews, case reports, letters to the editor and conference papers were also excluded.

The results of the searches were screened to meet the pre-defined eligibility criteria. A first selection was performed based on their titles, followed by a second selection performed by two independent reviewers (Y.Z. and W.W.), who reviewed the abstracts of all remaining records. Any disagreement in the selection of abstracts was resolved by consensus or by a third reviewer (B.F.). Full text articles for review and data processing were obtained for all selected abstracts.

Data extraction {#s2c}
---------------

Data were extracted from full text articles into a specially designed data extraction form by one reviewer (Y.Z.) in close consultation with another reviewer (M.E.). Any obscurities were discussed and decisions were taken by consensus. During the process of full text review and data extraction, studies were excluded if they did not fulfil the eligibility criteria or if the reported results were in a format that could not be used or were judged to be of insufficient quality. No investigators were contacted in the case of missing or obscure data.

The following data were extracted: authors, year of publication, title, study design, characteristics of the study population (e.g. study criteria, age, body weight/height/BMI, use of previous hormonal contraceptives), number of randomized, early discontinued and completed subjects, details on intervention (e.g. pill composition and regimen, multi- or monophasic, treatment duration and number of treatment groups), study objective, outcome parameters with special attention to the androgens and SHBG, sampling details (e.g. timing in treatment period and cycle day), analytical methods and statistical methods.

The study results \[mean and standard deviation (SD)\] for total T, free T and SHBG concentrations in International System (SI) units were extracted in a separate standardized form. In a few cases, study results were only presented in figures and data were obtained by measuring directly from these figures that were printed on a large scale. T concentrations reported in conventional units were converted to SI units using the following formula: conversion factor (CF) × conventional unit (e.g. gram) = SI (e.g. mol), where CF for T was 3.467. For the conversion of SHBG concentrations, the molecular weight of SHBG (43 780 g/mol) was used.

The standard error (SE) or SE of the mean (SEM) were converted to SD using the formula: SD = SEM × √*n*, where *n* is the sample size. In a few cases, neither the SD nor the SEM was reported. The SD was calculated if the SD (or SEM) was reported for the other time-points in the study using the following formula: SD~2~ = SD~1~ × (mean~2~/mean~1~), where SD~2~ is the SD which is unknown, SD~1~ is the SD reported for another time point in the study, mean~2~ is the mean that belongs to SD~2~ and mean~1~ the mean that belongs to SD~1~. A 95% confidence interval (CI) was converted to SD using the following formula: (CI~hi~ − CI~lo~)/((2 × 1.96) × √*n*), where CI~hi~ is the upper limit, CI~lo~ is the lower limit and *n* is the sample size. In cases where the change from baseline was reported, the end of treatment value was calculated from the baseline value minus the change from baseline. Finally, when a median plus range of variability was reported instead of a mean plus SD, the mean and SD were calculated by assuming the data had a log-normal distribution.

To prevent extraction errors, a quality control check between the final data used in the meta-analysis and the original publications was performed.

Critical appraisal {#s2d}
------------------

The risk of bias for the individual studies included in the meta-analysis was assessed based on guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions ([@DMT038C48]). All studies were critically appraised for selection bias (sequence generation, allocation concealment), performance bias, detection bias, attrition bias, reporting bias and other bias by two reviewers (Y.Z. and M.E.), in relation to the outcome parameters used in the meta-analysis. Studies were not excluded from the meta-analysis based on a high risk of bias, but their risk of bias was taken into consideration during the interpretation of the results.

Statistical analysis {#s2e}
--------------------

Only a few papers reported data from observational studies comparing women using COC with women not using COC (control group) and no specific type of COC was investigated in these studies. The majority of the selected studies were experimental studies investigating the effects of one or more COCs on different outcome parameters. Because an identical control group in these studies could not be identified, the experimental studies which compared the pretreatment study results (i.e. total T, free T and/or SHBG levels) with the end of treatment results were used in the meta-analysis. By using these studies, differences between the various types of COC could also be evaluated. In this context, an important additional inclusion criterion was used; study participants should not have taken a hormonal contraceptive prior to starting the study medication (including a wash-out period).

For the meta-analysis, the inverse variance method with random effects as analysis model was applied. As effect measures, the mean difference (MD) and associated 95% CIs were calculated based on the means of the pretreatment and the end of treatment levels of total T, free T and SHBG. Data of each treatment group were entered separately. For the end of treatment time point, the assessment (mean/SD) after a 6-cycle treatment duration was used for reasons of standardization. In cases where this time point was not reported, the three cycle or the nearest available reported time point was used.

In cases where the data showed large variation (e.g. larger SD in studies with larger mean values, plus identification of a significant heterogeneity in the meta-analysis), logarithms of these values were used to reduce the wide range of values. For the pooled concentrations in logarithmic scale, the generic inverse variance method with random effects was used. As effect measure, the relative change and associated 95% CI from pretreatment to end of treatment was calculated. Heterogeneity between the results of the different studies was examined using the *I*^2^ value. Heterogeneity was found to be significant when *I*^2^ \> 65%.

Subgroup analyses were performed for different estrogen doses (20--25 µg EE versus 30--35 µg EE) and for the type of progestin (first generation (estranes) versus second generation (gonanes) versus third generation (gonanes) versus fourth or unclassified generation) on all outcome parameters. The classification of the progestins was based on their chemical structure combined with the time of introduction.

As the methods to assess total T and free T concentrations could influence the outcome of the meta-analysis, subgroup analyses for the type of assay (RIA/ECLIA/enzyme-linked immunosorbent assay (ELISA) versus RIA with extraction/chromatography) and for the method to determine free T concentrations (direct immunoassay versus calculation or equilibrium dialysis) were performed. In cases where more than two subgroups were included and a significant difference was identified, it was pre-determined which subgroups would undergo separate statistical testing. For the progestin type, an additional comparison was made between second versus third generation or between second versus third generation, only including monophasic COCs containing 30--35 µg EE.

All analyses were performed with Review Manager (RevMan), version 5.2 (2012).

Results {#s3}
=======

Study selection {#s3a}
---------------

A flow chart of the included/excluded studies is shown in Fig. [1](#DMT038F1){ref-type="fig"}. Database searches yielded 904 records from MEDLINE, 929 from EMBASE and 538 from the Cochrane Central Register of Clinical Trials. Following the first review based on the title, 193 records remained (122 from MEDLINE, 39 from EMBASE and 32 from the Cochrane Central Register of Clinical Trials). After removal of duplicate records, 151 records remained and the abstracts were reviewed based on the pre-defined eligibility criteria. A total of 66 records were selected for full text review and data processing. During this phase, 27 papers were excluded, 3 studies were included by hand search and 42 studies were finally included in the meta-analysis. Table [I](#DMT038TB1){ref-type="table"} shows the reasons for exclusion. Not all studies reported all three outcome parameters, therefore 39 studies were included in the meta-analysis for COC effect on total T and SHBG and 29 studies were included for the effect on free T. Table IReasons for excluding articles.First author, yearReason[@DMT038C9]Wrong study population (women with impaired sexual function); baseline comparison problem group versus non-problem group, but only problem group takes part in study phase with prescribed study medication[@DMT038C14]Study results are reported as geometric mean, which could not be converted to mean; no SD or SE reported; unit of Free T (%) could not be converted[@DMT038C100]Treatment duration was unclear (i.e. from Day 5 to Day 25 and unclear if 21:7 regimen); not specified if results are reported in mean/SD; not clear if study participants had been using previous steroids prior to starting the study medication; not able to convert the unit of SHBG to SI units[@DMT038C51]Assumption same study as reported by [@DMT038C55]; the latter has been used in the meta-analysis, but publication of [@DMT038C51]) was also used to obtain additional information[@DMT038C53]The same study was published in an English journal by the same first author ([@DMT038C52]). The latter has been used in the meta-analysis, but this publication ([@DMT038C53]) was also used to obtain additional information[@DMT038C2]Observational study (COC users versus non-COC users); substudy of [@DMT038C10], [@DMT038C11]); various types of COCs were used[@DMT038C108]Study results are reported as geometric mean, which could not be converted to mean and SD is not reported. Results are only presented in figures with a low quality for direct measurement[@DMT038C10]Observational study (non-COC users versus users); various types of COCs were used; study results reported in two publications [@DMT038C10], [@DMT038C11])[@DMT038C11]Observational study (non-COC users versus users); various types of COCs were used; study results reported in two publications [@DMT038C10], [@DMT038C11])[@DMT038C96]Not able to obtain a copy of the full text[@DMT038C50]Not able to obtain a copy of the full text; assumption same study as reported by [@DMT038C49][@DMT038C79]Not able to obtain a copy of the full text[@DMT038C30]Wrong study population (women with acne, seborrhoea, hirsutism and alopecia)[@DMT038C20]Not able to obtain a copy of the full text; assumption same study as reported by [@DMT038C21][@DMT038C75]Not able to obtain a copy of the full text[@DMT038C104]Wrong study population (a part of the study population is post-partum \[given birth \<60 days of screening\] and results are not separately reported); units for the lab parameters are not specified[@DMT038C102]Not able to obtain a copy of the full text[@DMT038C3]Not able to obtain a copy of the full text[@DMT038C29]Pretreatment values for total T and free T were measured on Day 1 of treatment Cycle 1, which was directly after a 7-day pill-free period. This pill-free period followed the single dose administration part of the study (one tablet on Day 21 of menstrual cycle). This measurement is not a real pretreatment value. In addition, no SD or SEM reported for total T concentrations at pretreatment[@DMT038C76]Not able to obtain a copy of the full text[@DMT038C35]Publication combines results of two studies; results of one of these studies are also reported by [@DMT038C37]. The latter has been used in the meta-analysis, but publication of [@DMT038C35] was also used to obtain additional information[@DMT038C121]Results were judged to be of insufficient quality; SHBG converted, but after conversion values do not seem to be correct; all measurements for free T values during treatment are 2.08 pmol/l, therefore no SD can be reported (assumed that LOQ of assay was 2.08 pmol/l, therefore free T concentrations could not be measured and the LOQ has been reported.[@DMT038C93]Observational study and wrong study population (women are using a COC at pretreatment)[@DMT038C46]Observational study; no study medication; comparison between women with a normal sexual function and women with Hypoactive Sexual Desire Disorder of which half of the group was using hormonal contraception[@DMT038C90]Results were found to be of insufficient quality (e.g. not reported if results are expressed as mean/SD; seems that reported SD is sometimes the mean and vice versa \[see body weight\] and wrong numbers reported (e.g. baseline acne).[@DMT038C27]Study results are reported in boxplots from which no mean could be retrieved; no pretreatment assessment for COC-only group reported[@DMT038C44]Observational study; no study medication; study was performed to establish age-specific reference ranges for serum sex hormone concentrations in women (without and with hormonal contraception) using mass spectrometry (LC-MS/MS method) Figure 1Flowchart of the study selection process.

Characteristics of included studies {#s3b}
-----------------------------------

Characteristics of included studies are reported in Table [II](#DMT038TB2){ref-type="table"}. All 42 studies were experimental with one or more treatment groups. Only three studies used a double-blind or single-blind design ([@DMT038C119]; [@DMT038C37]; [@DMT038C61]). There were 21 studies which were non-comparative, whereas 16 studies compared two COCs and 5 studies compared 3 or more different types of COCs. Various types of COCs were investigated including both monophasic and multiphasic regimens. Almost all included studies investigated the effects of a COC with a 21:7 regimen, except for two studies that both included a COC with a 24:4 regimen ([@DMT038C25]; [@DMT038C4]). Most of the studies included COCs containing EE as the estrogenic component, but four studies ([@DMT038C119]; [@DMT038C25]; [@DMT038C4]; [@DMT038C19]) also investigated the effects of a COC with estradiol (E~2~) or E~2~ valerate. These treatments often did not qualify for the subgroup analyses. The duration of treatment varied from 1 treatment cycle ([@DMT038C57]) up to 12 treatment cycles ([@DMT038C52]; [@DMT038C6]; [@DMT038C118]; [@DMT038C91]). Treatment was assessed for 6 cycles (the effect measure used for the meta-analysis) in 16 studies, 3 cycles in 14 studies and for 12 studies another time point had to be taken for the analyses. Table IIDetails of studies included in meta-analysis.First author, yearStudy designStudy populationCharacteristics per treatment groupStudy treatment (duration, composition and regimen)End-points used in meta-analysisDetails hormone assessment (type of assay or calculation)Domains with low risk of bias (*n*)^1^Total testosteroneFree testosterone[@DMT038C22]Randomized, comparative, parallel groupHealthy women\
18--36 years\
regular menstrual cycle\
No hormonal contraceptives: ≥3 months1*n* = 10\
Mean age: NR\
Weight/BMI: NR3 cycles\
30 EE/150DSG 21:7Control cycle (day NR)\
Tr. cycle 3 (Day 21)Extraction/chromatography RIA\
Intra-assay CV: \<6%\
Inter-assay CV: \<10%\
LLQ: NRNot applicable52*n* = 10\
Mean age: NR\
Weight/BMI: NR3 cycles\
30 EE/150 LNG 21:7[@DMT038C36]^2^Comparative, parallel groupHealthy women\
20--30 years\
normal menstrual cycle\
No OC: not specified, but only normally cycling women were included1*n* = 5\
Mean age: NR\
Weight/BMI: NR2 cycles\
30 EE/300NG 21:7Control cycle (early proliferative phase and late luteal phase)\
Tr. Cycle 2 (Days 18--21)Extraction/chromatography RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRNot applicable42*n* = 5\
Mean age: NR2 cycles\
35 EE/400NET 21:7[@DMT038C110]Non-comparativeHealthy women\
20--23 years\
Normal menstrual cycle\
No OC: ≥2 months1*n* = 12\
Mean age: NR\
Weight/BMI: NR6 cycles\
30-40-30 EE/50-75-125 LNG\
(6-5-10), 21:7Control cycle (NR)\
Tr. cycle 6 (Days 18--21)RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NREquilibrium dialysis (measuring free fraction which is used to calculate the AFTC ([@DMT038C111])6[@DMT038C33]Comparative, parallel groupHealthy women\
No OC: ≥8 weeks1*n* = 13\
Mean age: 22.75 years\
Weight: NR (normal body weight)6 cycles\
30-40-30 EE/50-75-125 LNG\
(6-5-10), 21:7Control cycle (7 days before presumed menses)\
Tr. cycle 6 (Days 19--21)Extraction/chromatography RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRAFTC; calculated based on total T, SHBG and albumin ([@DMT038C111])52*n* = 13\
Mean age: 22.75 years\
Weight: NR (normal body weight)6 cycles\
50--50 EE/0-125DSG\
(7--14), 21:73*n* = 13\
Mean age: 22.75 years\
Weight: NR (normal body weight)6 cycles\
30 EE/150DSG 21:7[@DMT038C34]Comparative, parallel groupHealthy women\
No OC: ≥8 weeks1*n* = 22\
Mean (SE) age: 24.4 ± 1.6 years\
Mean (SE) weight: 57.6 ± 1.6 kg9 cycles\
50 EE/250 LNG 21:7Control cycle (7 days before presumed menses)\
Tr. cycle 6 (Days 19--21)Extraction/chromatography RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRAFTC; calculated based on total T, SHBG and albumin ([@DMT038C111])52*n* = 18\
Mean (SE) age: 20.9 ± 1.8 years\
Mean (SE) weight: 57.1 ± 1.8 kg9 cycles\
30-40-30 EE/50-75-125 LNG\
(6-5-10), 21:7[@DMT038C41]Comparative, parallel groupHealthy women\
20--36 years\
Regular menstrual cycle\
No OC: ≥3 months1*n* = 10\
Mean age: NR\
Weight/BMI: NR3 cycles\
30 EE/150DSG 21:7Control cycle (last few days)\
Tr. cycle 3 (Days 18--21)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRNot applicable52*n* = 10\
Mean age: NR\
Weight/BMI: NR3 cycles\
30 EE/150 LNG 21:7[@DMT038C95]^2^Open-label, non-comparativeAdolescent girls\
Regular menstrual cycle\
15--20 years\
No hormonal contraceptives: ≥12 months1*n* = 10\
Mean (SD) age: 17.0 ± 1.5 years\
Mean (SD) weight: 54.7 ± 4.6 kg6 cycles\
50 EE/1 mg lynestrenol OR\
35 EE/0.8 mg lynestrenol\
21:7Control cycle (\>Day 12; 1×/week)\
Tr. cycle 6 (2 times)RIA\
Intra-assay CV: 6%\
Inter-assay CV: 12%\
LLQ: NRRIA\
Intra-assay CV: 6%\
Inter-assay CV: 12%\
LLQ: NR6[@DMT038C55]^3^Randomized, crossover, comparative, parallel groupHealthy women\
24--35 years\
No OC: ≥3 months\
Control cycle: confirmed ovulation1*n* = 22\
Mean age: NR\
Weight/BMI: NR\
\
9 cycles\
30-40-30 EE/50-75-125 LNG (6-5-10), 21:7Control cycle (Day 21)\
Tr. cycle 3 (Day 21)Direct RIA\
Intra-assay CV: 7.2%\
Inter-assay CV: 8.1%\
LLQ: 0.87 nmol/lDirect RIA\
Intra-assay CV: 3.8%\
Inter-assay CV: 4.2%\
LLQ: 5.2 pmol/l52*n* = 22\
Mean age: NR\
Weight/BMI: NR9 cycles\
30 EE/150 DSG 21:7[@DMT038C31]Open-label, non-comparative, non-controlledHealthy women\
menstrual cycle\
22--38 years\
No hormonal contraceptives: ≥3 months1*n* = 39\
Mean (SD) age: 30.1 ± 4.5 years\
Mean (SD) weight: 56.4 ± 7.7 kg6 cycles\
20 EE/150DSG 21:7Control cycle (7 days before presumed menses)\
Tr. cycle 6 (day NR)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRDirect RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NR7[@DMT038C52]Randomized, comparative, parallel groupHealthy women\
18--35 years\
Regular menstrual cycle\
No OC: ≥3 months\
Control cycle: ovulation confirmed1*n* = 11\
Mean age: NR\
Weight/BMI: NR12 cycles\
30 EE/75 GSD 21:7Control cycle (Day 21)\
Tr. cycle 6 (Day 21)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRDirect RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NR42*n* = 11\
Mean age: NR\
Weight/BMI: NR12 cycles\
30 EE/150 DSG 21:7[@DMT038C73]Prospective, non-comparativeHealthy women\
18--35 years\
normal menstrual cycle\
No hormonal contraceptives: ≥3 months1*n* = 33\
Mean age: NR\
Weight/BMI: NR9 cycles\
35 EE/1000NET 21:7Control cycle (Days 1--5)\
Tr. cycle 6 (Days 1--5)Direct RIA\
Intra-assay CV: 1.5%\
Inter-assay CV: NR\
LLQ: 11 ng/dl (0.38 nmol/l)^4^ Not applicable7[@DMT038C82]Randomized, comparative, parallel groupHealthy women\
19--36 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥3 months1*n* = 17\
Mean age: 24.7 years\
Weight/BMI: NR6 cycles\
30--40-30 EE/50-75-125 LNG\
(6-5-10), 21:7Control cycle (luteal phase, Days 24--26)\
Tr. cycle 6 (Days 18--20)Direct RIA\
Intra-assay CV: 6%\
Inter-assay CV: 10%\
LLQ: NR Not applicable52*n* = 16\
Mean age: 24.7 years\
Weight/BMI: NR6 cycles\
30-40-30 EE/50-70-100 GSD\
(6-5-10), 21:7[@DMT038C24]Open-label, non-comparative, non-controlledHealthy women\
17--25 years\
No hormonal contraceptives: not specified, but pretreatment samples were collected during follicular phase, so assumption no OC prior IP1*n* = 10\
Mean age: NR\
Weight/BMI: NR6 cycles\
20 EE/150 DSG 21:7Control cycle (Days 8--10)\
Tr. cycle 6 (Days 16--19) Not applicableRIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NR7[@DMT038C57]Open-label, non-comparativeHealthy women\
19--34 years\
normal menstrual cycle\
No hormonal contraceptives: ≥2 months1*n* = 10\
Mean (SD) age: 31.7 ± 6.0 years\
Mean (SD) weight: 59.9 ± 4.5 kg1 cycle\
30-40-30 EE/50-70-100 GSD\
(6-5-10), 21:7Control cycle (Day 21)\
Tr. cycle 1 (Day 21)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: \<10%\
LLQ: 0.1 ng/mL (0.3 nmol/l)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: \<10%\
LLQ: 0.2 pg/ml (0.7 pmol/l)7[@DMT038C49]Randomized, comparative, parallel groupHealthy women\
18--38 years\
Regular menstrual cycle\
No hormonal contraceptives: not specified, but only women with regular menstrual cycle were included1*n* = 34\
Mean (SD) age: 24.7 ± 4.6 years\
Mean (SD) weight: 55.6 ± 6.5 kg6 cycles\
35 EE/180-215-250 NGM\
21:7Control cycle (follicular phase)\
Tr. cycle 6 (Days 1--6 and Days 14--28)Not reported\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NREquilibrium dialysis\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NR52*n* = 32\
Mean (SD) age: 26.1 ± 6.0 years\
Mean (SD) weight: 55.67 ± 6.1 kg6 cycles\
30-40-30 EE/50-75-125 LNG 21:7[@DMT038C97]^5^Randomized, comparative, parallel group, crossoverHealthy women\
Regular menstrual cycle\
No hormonal contraceptives: ≥3 months1*n* = 12\
Mean (SD) age: 32.2 ± 2.4 years\
Mean (SD) weight: 52.8 ± 4.8 kg\
\
3 cycles\
30 EE/150 DSG 21:7Control cycle (follicular phase, Days 6--9; luteal phase, Days 21--24)\
Tr. cycle 3 (Day 21)RIA\
Intra-assay CV: \<10%\
Inter-assay CV: \<10%\
LLQ: NR Not applicable42*n* = 12\
Mean (SD) age: 32.2 ± 2.4 years\
Mean (SD) weight: 52.8 ± 4.8 kg3 cycles\
20 EE/150 DSG 21:73*n* = 12\
Mean (SD) age: 32.2 ± 2.4 years\
Mean (SD) weight: 52.8 ± 4.8 kg3 cycles\
30 EE/150 LNG 21:7[@DMT038C56]Non-comparativeHealthy women\
20--29 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥3 months\
Control cycle: ovulation confirmed1*n* = 19\
Mean age: NR\
Weight/BMI: NR6 cycles\
40--30 EE/25--125 DSG\
(7--15), 21:7Control cycle (Days 21--24)\
Tr. cycle 6 (Days 18--22)Direct RIA\
Intra-assay CV: 7.6%\
Inter-assay CV: 8.2%\
LLQ: NRDirect RIA\
Intra-assay CV: 3.8%\
Inter-assay CV: 4.2%\
LLQ: NR7[@DMT038C58]Open-label, non-comparative\
\
Healthy women\
18--32 years\
No OC: ≥2 months1*n* = 14\
Mean (SD) age: 27 ± 5 years\
Mean (SD) weight: 66 ± 6 kg3 cycle\
30-40-30 EE/50-70-100 GSD\
(6-5-10), 21:7Control cycle (day NR)\
Tr. cycle 3 (Day 21)Direct RIA\
Intra-assay CV: 8%\
Inter-assay CV: 8%\
LLQ: NRDirect RIA\
Intra-assay CV: 4%\
Inter-assay CV: 8--14%\
LLQ: NR7[@DMT038C59]Open-label, non-comparativeHealthy women\
normal menstrual cycle\
No hormonal contraceptives: ≥2 months1*n* = 15\
Mean (SD) age: 26 ± 6 years\
Mean (SD) weight: 63 ± 7 kg3 cycles\
35 EE/2 mg CPA 21:7Control cycle (day NR)\
Tr. cycle 3 (Day 21)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: 8--12%\
LLQ: NRDirect RIA\
Intra-assay CV: NR\
Inter-assay CV: 5--9%\
LLQ: NR7[@DMT038C6]Randomized, double-blind, comparative, parallel groupHealthy women\
18--40 years\
No OC: ≥2 months1*n* = 25\
Mean age: 25.0 years\
Weight/BMI: NR12 cycles\
20 EE/150 DSG 21:7Control cycle (Days 18--21)\
Tr. cycle 6 (Days 18--21)Direct RIA\
CV: 6.5--8.9% at 3 nmol/l\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRCalculated based on total T, SHBG and albumin ([@DMT038C63])\
CV: 8.5--12.6% at 50 pmol/l62*n* = 26\
Mean age: 21.8 years\
Weight/BMI: NR12 cycles\
30 EE/150 DSG 21:7[@DMT038C60]Open-label, non-comparativeHealthy women\
No OC: ≥2 months1*n* = 14\
Mean (SD) age: 23 ± 3 years\
Mean (SD) weight: 61 ± 8 kg3 cycles\
30--40-30 EE/50-75-125 LNG\
(6-5-10), 21:7Control cycle (day NR)\
Tr. cycle 3 (Day 21)Direct RIA\
Intra-assay CV: \<10%\
Inter-assay CV: 4--8%\
LLQ: NRDirect RIA\
Intra-assay CV: \<10%\
Inter-assay CV: 7--8%\
LLQ: NR7[@DMT038C116]^2^Open-label, non-comparative\
\
Healthy women\
17--35 years\
normal menstrual cycle\
No hormonal contraceptives: ≥3 months1*n* = 30\
Mean (SD) age: 23.2 ± 5.21 years\
Weight/BMI: NR9 cycles\
40-25 EE/30-125 DSG\
(7--15), 21:7Control cycle (Day 22)\
Tr. cycle 6 (Day 22)Direct RIA\
Intra-assay CV: 6.5%\
Inter-assay CV: 8.4%\
LLQ: 0.1 ng/mL (0.3 nmol/l)Direct RIA\
Intra-assay CV: 3.5%\
Inter-assay CV: 4.5%\
LLQ: 0.15 pg/ml (0.5 pmol/l)7[@DMT038C47]Open-label, non-comparativeHealthy women\
No OC: ≥2 months1*n* = 14\
Mean (SD) age: 27.9 ± 3.9 years\
Mean (SD) weight: 65.5 ± 11.8 kg3 cycles\
20 EE/75 GSD 21:7Control cycle (Day 21)\
Tr. cycle 3 (Day 21)Direct RIA\
Intra-assay CV: \<10%\
Inter-assay CV: 4--8%\
LLQ: NRDirect RIA\
Intra-assay CV: \<10%\
Inter-assay CV: 7--8%\
LLQ: NR7[@DMT038C72]Randomized, comparative, parallel groupHealthy women\
18--35 years\
Regular menses (every 25--35 days)\
No OC: ≥12 months1*n* = 20\
Mean age: 25.8 years\
BMI: 21.7 kg/m^2^6 cycles\
50 EE/1 mg NET 21:7Control cycle (Day 21)\
Tr. cycle 6 (Day 21)Direct RIA\
Intra-assay CV: 5%\
Inter-assay CV: NR\
LLQ: 4 ng/dl (0.1 nmol/l)Not applicable72*n* = 20\
Mean age: 23.5 years\
BMI: 21.5 kg/m^2^6 cycles\
35 EE/1 mg NET 21:73*n* = 20\
Mean age: 24.3 years\
BMI: 21.4 kg/m^2^6 cycles\
35 EE/0.5 mg NET 21:7[@DMT038C118]Comparative, parallel groupHealthy women\
18--36 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥3 months\
Control cycle: ovulation confirmed1*n* = 26\
Mean age: NR\
Weight/BMI: NR12 cycles\
30-40-30 EE/50-70-100 GSD\
(6-5-10), 21:7Control cycle (Day 21)\
Tr. cycle 6 (Day 21)Direct RIA\
Intra-assay CV: 7.6%\
Inter-assay CV: 8.2%\
LLQ: 0.08 ng/mL (0.3 nmol/l)Direct RIA\
Intra-assay CV: 3.8%\
Inter-assay CV: 4.2%\
LLQ: 0.15 pg/ml (0.5 pmol/l)52*n* = 26\
Mean age: NR\
Weight/BMI: NR12 cycles\
35 EE/250 NGM 21:7[@DMT038C21]Randomized, open-label, comparative, parallel groupHealthy women\
18--38 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥2 months1*n* = 25\
Mean (SD) age: 26.9 ± 4.2 years\
Mean BMI: 22.2 ± 2.3 kg/m^2^\
\
6 cycles\
35 EE/250 NGM 21:7Control cycle (luteal phase, Days 24--27)\
Tr. cycle 6 (Days 18--21)Extraction/chromatography RIA\
Intra-assay CV: 5.6%\
Inter-assay CV: 6.9%\
LLQ: NRDirect RIA\
Intra-assay CV: 6.4%\
Inter-assay CV: 12.1%\
LLQ: NR52*n* = 25\
Mean (SD) age: 26.3 ± 4.9 years\
Mean (SD) weight: 22.2 ± 2.4 kg\
\
6 cycles\
30 EE/75 GSD 21:73*n* = 25\
Mean (SD) age: 27.1 ± 5.1 years\
Mean (SD) weight: 22.2 ± 2.4 kg\
\
6 cycles\
30 EE/150 DSG 21:74*n* = 25\
Mean (SD) age: 27.3 ± 5.3 years\
Mean (SD) weight: 22.4 ± 2.2 kg\
\
6 cycles\
20 EE/150 DSG 21:7[@DMT038C101]Non-comparativeHealthy women\
20--34 years\
normal menstrual cycle\
No hormonal contraceptives: not specified, but women had to have a normal menstrual cycle1*n* = 24\
Mean (SD) age: 27.5 ± 4.3 years Weight/BMI: NR3 cycles\
20 EE/100 LNG 21:7Control cycle (day 20)\
Tr. cycle 3 (Day 20)Direct RIA\
Intra-assay CV: 5--9%\
Inter-assay CV: 5--9%\
LLQ: NRDirect RIA\
Intra-assay CV: 5--9%\
Inter-assay CV: 5--9%\
LLQ: NR7[@DMT038C1]Randomizsed, crossover, comparativeHealthy women\
21--32 years\
Regular menstrual cycle\
No OC: ≥2 months control cycle: ovulation confirmed1*n* = 29\
Mean age: NR\
Weight/BMI: NR3 cycles\
30-40-30 EE/50-75-150 LNG\
(6-6-9), 21:7\
\
Control cycle (Day 21)\
Tr. cycle 3 (Day 21)Direct RIA\
Intra-assay CV: 5.1%\
Inter-assay CV: 10.4%\
LLQ: 0.2 ng/ml (0.7 nmol/l)Direct RIA\
Intra-assay CV: 3.8%\
Inter-assay CV: 4.2%\
LLQ: 0.6 pg/ml (2.1 pmol/l)72*n* = 26\
Mean age: NR\
Weight/BMI: NR3 cycles\
30-40-30 EE/50-75-150 LNG\
(6-5-10), 21:7[@DMT038C106]Randomized, open-label, comparative, parallel groupHealthy women\
18--28 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥3 months1*n* = 27\
Mean (SD) age: 22.9 ± 2.8 years\
Mean (SD) weight: 74.9 ± 25.0 kg\
\
3 cycles\
20 EE/100 LNG 21:7Control cycle (day NR)\
Tr. cycle 3 (Days 17--21)Extraction/chromatography RIA\
Intra-assay CV: 5--10%\
Inter-assay CV: 10--15%\
LLQ: NR Not applicable52*n* = 25\
Mean (SD) age: 22.5 ± 3.0 years\
Mean (SD) weight: 67.5 ± 16.2 kg\
\
3 cycles\
20 EE/1 mg NETA (plus ferrous fumarate on non-hormonal days, Loestrin®) 21:7[@DMT038C15]^6^Non-randomized, open-label, non-comparativeHealthy women\
20--39 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥6 months (implants/OC) or ≥12 months (injectables)1*n* = 17\
Mean age: NR\
Weight range: 52.6--141 kg3 cycles\
20-30-35/1 mg NETA (5-7-9), 21:7Control cycle (Days 3, 4, 5, 10, 11, 12, 19, 20 and 21)\
Tr. cycle 3 (Day 21)Extraction/chromatography RIA\
Intra-assay CV (%RSD): \<8.1%\
Inter-assay CV (%RSD): \<13.4%\
LLQ: 3 ng/dL (0.1 nmol/l)Equilibrium dialysis\
Intra-assay CV (%RSD): \<6.86%\
Inter-assay CV (%RSD): \<10.9%\
LLQ: 0.1% free5[@DMT038C119]Randomized, double-blind, comparative, parallel groupHealthy women\
18--35 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥4 weeks\
Control cycle: ovulation confirmed1*n* = 25\
Mean age: NR\
Weight/BMI: NR6 cycles\
30 EE/2 mg DNG 21:7Control cycle (Days 21--26)\
Tr. cycle 6 (Days 18--21)Not applicableDirect RIA\
Intra-assay CV: 23.7%\
Inter-assay CV: 24.1%\
LLQ: 0.15 pg/ml (0.5 pmol/l)52*n* = 25\
Mean age: NR\
Weight/BMI: NR6 cycles\
20 EE/2 mg DNG 21:73*n* = 25\
Mean age: NR\
Weight/BMI: NR6 cycles\
10 EE/E2 V/2 mg DNG, 21:74*n* = 25\
Mean age: NR\
Weight/BMI: NR6 cycles\
20 EE/100 LNG 21:7[@DMT038C83]^2^Open-label, non-comparativeHealthy women\
16--35 years\
Regular menstrual cycle\
No hormonal contraceptives: not specified, but only women with regular menstrual cycles were included1*n* = 12\
Mean (SD) age: 20.9 ± 4.2 years\
BMI: 19.9 ± 1.4 kg/m^2^10 cycles\
30 EE/150 LNG 21:7Control cycle (day NR)\
Tr. cycle 10 (day NR)Direct RIA\
Intra-assay CV: 6%\
Inter-assay CV: 10%\
LLQ: 0.1 nmol/lCalculated based on total T, SHBG and fixed albumin \[40 g/l\] ([@DMT038C98])\
\
7[@DMT038C117]^2^Randomized, comparative, parallel groupHealthy women\
18--40 years\
regular menstrual cycle (25--35 days)\
No hormonal contraceptives: ≥3 months1*n* = 9\
Mean (SD) age: 25.1 ± 2.8 years\
BMI: 21.8 ± 3.4 kg/m^2^3 cycles\
35 EE/250 NGM 21:7Control cycle (day NR)\
Tr. cycle 3 (Days 17--21)Extraction/chromatography RIA\
Intra-assay CV: 4--7%\
Inter-assay CV: 9--12%\
LLQ: NRCalculated based on total T, SHBG and albumin ([@DMT038C112])\
 5[@DMT038C28]^2^Randomized, prospective, comparative, parallel groupHealthy women\
18--40 years\
No hormonal contraceptives: ≥2 months\
control cycle: ovulation confirmed1*n* = 31\
Mean (SD) age: 29.5 ± 4.7 years\
BMI: 29.5 ± 6.8 kg/m^2^5 cycles\
20 EE/100 LNG 21:7Control cycle (Days 2--5)\
Tr. cycle 5 (Days 8--21)ECLIA\
Intra-assay CV: \<10%\
Inter-assay CV: \<10%\
LLQ: NR Not applicable6[@DMT038C37]Randomized, single-blind comparative, parallel groupHealthy women\
≥8 years\
Regular menstrual cycle\
No OC: ≥3 months1*n* = 24\
Mean (SD) age: 19.7 ± 2.2 years\
Weight/BMI: NR3 cycles\
35 EE/180-215-250 NGM, 21:7Control cycle (2 days around ovulation)\
Tr. cycle 2 (Days 12--14)Direct RIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRMethod used is based on centrifugal ultrafiltration dialysis;\
calculated from a normogram constructed using serum SHBG and %FT ([@DMT038C40]); free T can then be determined from T ([@DMT038C42])62*n* = 24\
Mean (SD) age: 19.9 ± 1.3 years\
Weight/BMI: NR3 cycles\
25 EE/180-215-250 NGM, 21:7[@DMT038C61]^2^Randomized, double-blind, comparative, parallel groupHealthy women\
No OC: ≥3 months\
normal menstrual cycle (21--35 days)\
non-smoking1*n* = 31\
Mean (SD) age: 27.5 ± 4.7 years\
Mean (SD) weight: 67.7 ± 13.9 kg6 cycles\
20 EE/1 mg NET 21:7Control cycle (Days 15--21)\
Tr. cycle 6 (days 15--21)Direct RIA\
Intra-assay CV: \<10%\
Inter-assay CV: \<10%\
LLQ: NR Not applicable7[@DMT038C91]^2^Randomized, prospective, comparative, parallel groupHealthy women\
18--40 years\
Regular menstrual cycle\
No hormonal contraceptives: ≥4 weeks1*n* = 29\
Mean (SD) age: 24.6 ± 3.2 years\
Mean (SD) weight: 63.7 ± 8.0 kg12 cycles\
30 EE/2 mg DNG 21:7Control cycle (Days 21--26)\
Tr. cycle 4 (Days 19--21)CLIA\
Intra-assay CV: 4.6%\
Inter-assay CV: 7.4%\
LLQ: 0.07 nmol/lDirect RIA\
Intra-assay CV: 12.3%\
Inter-assay CV: 18.3%\
LLQ: 0.52 pmol/l7[@DMT038C25]Randomized, open-label, comparative, parallel groupHealthy women\
18--35 years\
No hormonal contraceptives: not specified, but women using OC and only after return of spontaneous menses control cycle was started (= at least 2 cycles no OC)\
Control cycle: ovulation confirmed1*n* = 32\
Mean (SD) age: 22.8 ± 3.3 years\
Mean (SD) weight: 68.5 ± 12.3 kg6 cycles\
1.5 mg E2/2.5 mg NOMAC, 24:4Control cycle (Days 5--7)\
Tr. cycle 6 (Days 21)ECLIA\
Intra-assay CV: NR\
Inter-assay CV: 1.9--3.7%\
LLQ: NRCalculated based on total T, SHBG and albumin ([@DMT038C112])\
 72*n* = 16\
Mean (SD) age: 22.9 ± 4.3 years\
Mean (SD) weight: 66.3 ± 10.4 kg6 cycles\
30 EE/3 DRSP 21:7[@DMT038C103]Randomized, prospective, open-label, comparative, parallel groupHealthy women\
18--40 years\
No hormonal contraceptives: ≥3 months1*n* = 51\
Mean (SD) age: 28.7 ± 6.83 years\
Mean (SD) weight: 60.6 ± 3.0 kg6 cycles\
30 EE/150 LNG 21:7Control cycle (Days 2--4)\
Tr. cycle 6 (Days 2--4)CMIA\
Total precision: 3.1--8.0%\
LLQ: 0.28 nmol/lNot applicable72*n* = 50\
Mean (SD) age: 26.8 ± 5.89 years\
Mean (SD) weight: 62.5 ± 12.6 kg6 cycles\
20 EE/100 LNG 21:7[@DMT038C4]Randomized, open-label, comparative, parallel groupHealthy women\
18--50 years\
No OC: 6 weeks1*n* = 60\
Mean (SD) age: 28.2 ± 8.2 years\
Mean (SD) weight: 62.8 ± 9.7 kg\
\
6 cycles\
1.5 mg E2/2.5 mg NOMAC, 24:4Control cycle (follicular phase, nd half)\
Tr. cycle 6 (Days 15--21)ECLIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRCalculated based on total T, SHBG and albumin ([@DMT038C112])72*n* = 58\
Mean (SD) age: 29.1 ± 7.8 years\
Mean (SD) weight: 61.7 ± 9.0 kg6 cycles\
30 EE/150 LNG 21:7[@DMT038C19]Prospective, open-label, non- comparativeHealthy women\
18--48 years\
No hormonal contraceptives: duration not specified\
Control cycle: ovulation confirmed1*n* = 57\
Mean (SD) age: 28.7 ± 3.3 years\
BMI: 21.3 ± 3.7 kg/m^2^6 cycles\
2--3 mg E2 V/3-2-1 mg DNG 21:7Control cycle (follicular phase, Days 5--8)\
Tr. cycle 6 (Days 5--8)\
\
ELISA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRNot applicable7[@DMT038C12]Pilot, non-comparativeYoung eumenorrheic, healthy women\
normal menstrual cycle\
No hormonal contraceptives: at least 6 months1*n* = 22\
Mean (SD) age: 25.0 ± 2.8 years\
BMI: 21.7 ± 3.2 kg/m^2^3 cycles\
30 EE/3 mg DRSP 21:7Control cycle (Days 3--5)\
Tr. cycle 3 (Days 3--5)ECLIA\
Intra-assay CV: NR\
Inter-assay CV: NR\
LLQ: NRNot applicable7[^1][^2]

The total number of women randomized in all studies was 1495 with an average number of 21 (range 5--60) women per treatment group. The study population consisted of healthy women in the age range of 18--40 years. Two studies ([@DMT038C95]; [@DMT038C24]) also enrolled younger women (minimum age of 15 and 17 years, respectively). One study enrolled Chinese women ([@DMT038C97]). The period without intake of hormonal contraceptives before the start of the study was more than 2 or 3 months in most studies, ranging from 4 to 6 weeks ([@DMT038C119]; [@DMT038C91]; [@DMT038C4]) up to 6 months ([@DMT038C15]; [@DMT038C12]) and 12 months ([@DMT038C95]; [@DMT038C72]). For those studies that did not specify a pre-study period without hormonal contraceptives, a regular menstrual cycle with or without proven ovulation was an inclusion criterion ([@DMT038C36]; [@DMT038C24]; [@DMT038C49]; [@DMT038C101]; [@DMT038C83]; [@DMT038C25]; [@DMT038C19]).

With regard to the methods to determine total T and free T concentrations, 30 studies used a direct immunoassay, 9 studies incorporated an extraction/chromatography step before RIA and no studies used the LC-MS/MS method. One study did not specify the type of assay used to measure total T concentrations ([@DMT038C49]). The free T concentrations were analysed by a direct immunoassay in 18 studies, determined by calculation (based on total T, SHBG and albumin concentrations) in 8 studies and by equilibrium dialysis in 3 studies. Five studies used the formula of [@DMT038C111], [@DMT038C112]).

Methodological quality {#s3c}
----------------------

Outcome parameters used in the meta-analysis and the type of comparison (a within-subject comparison on pretreatment (no COC) versus end of treatment (COC) were assessed for risk of bias. An overview of the risk of bias of the studies included in the meta-analysis is provided in Table [II](#DMT038TB2){ref-type="table"} and [Supplementary data, Table SI](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1).

To assess selection bias, reported procedures on sequence generation and allocation concealment were judged for all studies. Often randomization and concealment was not applicable for studies, because only one treatment group was investigated. Furthermore, selection bias was expected not to have a major impact on the outcome of the analyses as study participants acted as their own control. Overall, three studies ([@DMT038C36]; [@DMT038C34]; [@DMT038C41]) were judged as having inadequate sequence generation or allocation concealment (high risk of bias). In many studies the procedures were not clearly described and no judgement on risk of bias could be made ([@DMT038C22]; [@DMT038C33]; [@DMT038C55]; Jung-[@DMT038C52], [@DMT038C53]; [@DMT038C82]; [@DMT038C49]; [@DMT038C97]; [@DMT038C118]; [@DMT038C21]; [@DMT038C106]; [@DMT038C119]; [@DMT038C117]). With regard to performance and detection bias, it was assumed that lack of blinding of participants and personnel or lack of blinding of outcome assessment were not likely to have had an influence on the measurement of the biochemical outcome parameters. Therefore, risk of performance and detection bias was judged as not relevant and was considered to be low for all studies. On the other hand, incomplete outcome data (attrition bias) was found to be important, as missing data could potentially have an impact on the observed effect size. Reasons for early discontinuation could be due to being lost to follow-up, or could be related to side effects associated with low androgen levels (e.g. emotionally labile, lack of sexual desire). For the judgement of attrition bias, it was assumed that a completion rate of ≥ 80% per treatment group had not affected the outcome. Ten studies were considered to have a high risk of attrition bias ([@DMT038C6]; [@DMT038C106]; [@DMT038C117]; [@DMT038C28]; [@DMT038C37]) or an unclear risk ([@DMT038C36]; [@DMT038C110]; [@DMT038C95]; [@DMT038C52], [@DMT038C53]; [@DMT038C15]). The reporting bias (selective outcome reporting) was difficult to assess due to the lack of study protocols. For all studies it was verified whether the reported laboratory parameters were in adherence to the objectives of the study as specified in the paper. This was also done for the reported statistical significances. One study ([@DMT038C15]) was judged as having a high risk of reporting bias, because total T results were not reported. Finally, all studies were also judged for other possible sources of bias. The only additional source for bias was the inadequate statistics used in a crossover study pooling the data for both treatment groups ([@DMT038C97]).

Several other issues were identified that were not considered as a source for bias, but could still have affected the outcome of the analyses. In one study, only Chinese women were enrolled ([@DMT038C97]). Some of the procedures performed during data extraction (e.g. obtaining values from figures, converting SEM to SD, converting to SI units were considered not to cause bias, but they could potentially cause some inaccuracy in the data used for the analyses. This is also applicable for calculating missing SDs based on SDs that were available for other time points in the study or based on 95% CI ([@DMT038C36]; [@DMT038C73]; [@DMT038C60]; [@DMT038C72]; [@DMT038C61]). Furthermore, for some studies the reported units or measures for variation (SEM) did not seem correct in view of the expected ranges and assumptions were made for correction ([@DMT038C36]; [@DMT038C31]; [@DMT038C117]). Most of the studies did perform their sampling at the end of the pill cycle just prior to the pill-free period (e.g. on Days 19--21); however, in a few studies samples were collected during the first week ([@DMT038C73]; [@DMT038C103]; [@DMT038C19]; [@DMT038C12]). One study ([@DMT038C72]) retrospectively collected samples from a larger study. Although steroids are known to be stable when stored for a longer period, it could be possible that there is some *in vitro* effect during storage, which could result in small deviations of the results. Finally, in one study ([@DMT038C95]) two different COCs were used in one treatment group (50 µg EE/1 mg lynestrenol and 35 µg EE/0.8 mg lynestrenol), and this study was excluded from the subgroup analyses between the different EE dosages. These issues are not considered as bias, but could be a source for heterogeneity.

Effect of COC treatment on total testosterone, SHBG and free testosterone concentrations {#s3d}
----------------------------------------------------------------------------------------

The results of the analyses including the different subgroup analyses can be found in Table [III](#DMT038TB3){ref-type="table"} and [Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1). Table IIISummary of key findings of the meta-analysis on the effect of COCs on total T, free T and SHBG concentrations with the comparison no COC (pretreatment) versus COC (end of treatment).Type of analysisNumber of studiesNumber of treatment groupsNumber of subjects Total (no COC versus COC)MD \[95% CI\]*P* valueHeterogeneity (*I*^2^) (%)COC effect on total T \[nmol/l\]39642741 (1405 versus 1336)−0.49 \[−0.55, −0.43\]\<0.00155 Subgroup: type of progestin39612452 (1256 versus 1196)−0.50 \[−0.56, −0.43\]0.2034.7  First generation (estranes)8313 (159 versus 154)−0.33 \[−0.50, −0.17\]  Second generation (gonanes)21934 (474 versus 460)−0.54 \[−0.63, −0.45\]  Third generation (gonanes)281044 (542 versus 502)−0.51 \[−0.62, −0.40\]  Fourth or unclassified generation4161 (81 versus 80)−0.52 \[−0.77, −0.27\]COC effect on SHBG \[nmol/l\]39672917 (1487 versus 1430)99.10 \[86.44, 111.75\]\<0.00196 Subgroup: type of progestin38642628 (1338 versus 1290)103.09 \[89.51, 116.66\]\<0.00197.8  First generation (estranes)9347 (176 versus 171)89.06 \[65.94, 112.19\]  Second generation (gonanes)20934 (470 versus 464)35.84 \[26.86, 44.82\]  Third generation (gonanes)281036 (536 versus 500)136.76 \[120.66, 152.86\]  Fourth or unclassified generation7311 (156 versus 155)157.39 \[111.62, 203.16\]\[95% CI\]COC effect on free T (log scale; relative change)29472043 (997 versus 1046)0.39 \[0.35, 0.43\]\<0.00179 Subgroup: type of progestin29451865 (954 versus 911)0.38 \[0.35, 0.42\]0.3212.0  First generation (estranes)254 (27 versus 27)0.38 \[0.31, 0.48\]  Second generation (gonanes)13596 (302 versus 294)0.42 \[0.36, 0.50\]  Third generation (gonanes)24946 (490 versus 456)0.37 \[0.32, 0.43\]  Fourth or unclassified generation6269 (135 versus 134)0.34 \[0.25, 0.46\][^3]

Effect of COC treatment on total testosterone concentrations {#s3e}
------------------------------------------------------------

A total of 39 studies and 64 treatment groups were included in the meta-analysis for the effect of COC treatment on total T levels with data from 1405 women (no COC) versus 1336 women (COC). The pooled total T concentration at the end of treatment was significantly (*P* \< 0.001) lower than the pooled total T concentration at pretreatment. No significant between-study heterogeneity was found (Table [III](#DMT038TB3){ref-type="table"} and Fig. [2](#DMT038F2){ref-type="fig"}). Figure 2Meta-analysis of 39 studies on the effect of COCs on total T concentrations. COC, combined oral contraceptive; T, testosterone.

The suppressive effect of COCs on total T did not reveal a significant difference (*P* = 0.54) between the COCs containing 20--25 µg EE dose and the COCs containing 30--35 µg EE ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S1](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). The subgroup analysis between the different types of progestin (first generation versus second generation versus third generation versus fourth or unclassified generation) also revealed no significant difference (*P* = 0.20) between the groups for the effect on total T (Table [III](#DMT038TB3){ref-type="table"} and Fig. [3](#DMT038F3){ref-type="fig"}). When a more detailed comparison was made combining the EE dose and the type of progestin, a significant difference was found between the subgroups (*P* = 0.02). In particular, the first and second generation COCs containing 20--25 µg EE showed less suppressive effects on total T than did the other subgroups ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S2](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). A separate analysis comparing the second and third generation monophasic COCs containing 30--35 µg EE revealed no differences between progestins on total T levels (Fig. [3](#DMT038F3){ref-type="fig"} [Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1), [Figs S1, S2 and S3](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). For all these subgroup analyses, no significant heterogeneity was found (Table [III](#DMT038TB3){ref-type="table"} and [Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). Figure 3Subgroup analysis for the effect of type of progestin on total T concentrations in the meta-analysis. COC, combined oral contraceptive; T, testosterone.

For the comparison between the methods used to measure total T, lower differences in total T concentrations were reported with the RIA incorporating extraction or chromatography compared with the assays without this extra step. This difference was statistically significant (P = 0.003); however, a significant heterogeneity was also identified ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S4](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)).

Effect of COC treatment on SHBG concentrations {#s3f}
----------------------------------------------

The 39 studies and 67 treatment groups included in the meta-analysis reported data on 1430 women being treated with COC. The pooled SHBG concentration was significantly (P \< 0.001) higher at the end of treatment than at pretreatment. The increase in SHBG levels was significantly (*P* = 0.05) less after treatment with COCs containing 20--25 µg EE compared with COCs containing 30--35 µg EE ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S5](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). A more pronounced and significantly different effect was observed with different types of progestins in the subgroup analysis (*P* \< 0.001). Treatment with second generation COCs resulted in the least increase in SHBG, whereas treatment with the third and fourth generation COCs resulted in the highest increase (Table [III](#DMT038TB3){ref-type="table"} and Fig. [5](#DMT038F5){ref-type="fig"}). When performing a subgroup analysis combining the estrogen dose with the progestin type, a significant difference (*P* \< 0.001) was found. The COCs with a second generation progestin and containing the lower 20--25 µg EE dose caused the lowest increase of SHBG ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S6](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). An additional subgroup analysis comparing the second and third generation monophasic COCs containing 30--35 µg EE confirmed that the second generation progestin had significantly less effect on SHBG (*P* \< 0.001) ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S7](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). For all comparisons made with the pooled SHBG concentrations, significant heterogeneity was identified (Table [III](#DMT038TB3){ref-type="table"}, Figs [4](#DMT038F4){ref-type="fig"}, [5](#DMT038F5){ref-type="fig"} and [Supplementary data, Table SII, Figs S5, S6, S7](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). Figure 4Meta-analysis of 39 studies on the effect of COCs on SHBG concentrations. COC, combined oral contraceptive; SHBG, sex hormone-binding globulin. Figure 5Subgroup analysis for the effect of type of progestin on SHBG concentrations in the meta-analysis. COC, combined oral contraceptive; SHBG, sex hormone-binding globulin.

Effect of COC treatment on free testosterone concentrations {#s3g}
-----------------------------------------------------------

The 29 studies and 47 treatment groups used for the meta-analysis for the COC effect on free T concentrations included 1046 women at pretreatment and 997 women at end of treatment. The levels of free T showed a large variation. After inspection of the data, it was decided to use a logarithmic scale for the free T concentrations with the relative change as the effect measure. At the end of COC use, the free T levels were significantly (*P* \< 0.001) decreased. The average relative change was 0.39, which means that the free T levels were 61% lower compared with the levels before starting the COC (Table [III](#DMT038TB3){ref-type="table"} and Fig. [6](#DMT038F6){ref-type="fig"}). No significant difference in treatment effect was found after performing subgroup analyses for comparison between the EE dosages and between the type of progestins or when combining the EE dosage with the type of progestin (Table [III](#DMT038TB3){ref-type="table"}, Figs [6](#DMT038F6){ref-type="fig"}, [7](#DMT038F7){ref-type="fig"}, [Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1), [Figs S8](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [S9](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). Significant heterogeneity was found for the main analysis, but not for the subgroup analyses (Table [III](#DMT038TB3){ref-type="table"} and [Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)). Figure 6Meta-analysis of 29 studies on the effect of COCs on free T concentrations (log scale; relative change). COC, combined oral contraceptive; T, testosterone. Figure 7Subgroup analysis for the effect of type of progestin on free T concentrations in the meta-analysis on free T (log scale; relative change). T, testosterone.

To judge whether the methods to assess the free T levels had any effect on the size of the observed effect, a subgroup analysis between the different methods was performed. No significant difference (*P* = 0.27) in pooled free T concentration was found between the results obtained by direct RIA and with the methods reported to be more accurate (calculation or equilibrium dialysis). No significant between-study heterogeneity was found ([Supplementary data, Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) and [Supplementary data, Fig. S10](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1)).

Discussion {#s4}
==========

This systematic review and meta-analysis was performed to evaluate the effect of COCs on concentrations of total T, free T and SHBG in healthy women. A total of 42 studies involving 1495 women were included in the current analyses. Both pooled total T and free T concentrations decreased significantly following COC use. All studies reported such an effect, except one ([@DMT038C49]). The suppression of free T was twice as high compared with total T. The decline in total T and free T levels were both independent from the estrogen dose or progestin type. SHBG levels increased significantly during COC use, as reported by all included studies. The lower dosage of EE had less of an effect on SHBG than the higher dosage, and the greatest effect was with the COCs containing a third or fourth generation progestin. The COCs with a second generation progestin caused the smallest increase in SHBG. The between-study heterogeneity was acceptable for all comparisons with total T and the subgroup comparisons with free T. However, a significant heterogeneity was found for the analyses with SHBG and for the main analysis with free T.

The between-study heterogeneity can be explained by the different types of COCs that were investigated in the included studies. Additionally, the duration without the use of a hormonal contraceptive prior to starting the COC varied from 1 month to 12 months. Another explanation may be the difference in handling of blood samples and assessment methods. Timing of blood sampling was not always consistent among studies. Most of the studies performed their sampling just prior to the start of the pill-free period, whereas a few studies ([@DMT038C73]; [@DMT038C103]; [@DMT038C19]; [@DMT038C12]) collected samples during the first week of the cycle. Some studies did not provide information on the sampling time points, so it could be that no specific time window was followed. The sample timing could be an important factor when evaluating the effect of COC use on hormonal parameters. The fact that some studies measured the hormone concentrations in plasma and some in serum could also be a confounding factor, although this is mainly overcome by the within-subject comparison used in the current meta-analysis. Furthermore, there is no consensus on adequate methods for measuring total T as well as free T concentrations and its standardization ([@DMT038C113]; [@DMT038C62]; [@DMT038C87]; [@DMT038C115]; [@DMT038C44]), which is apparent from the studies using different types of analytical methods.

The subgroup analysis between the studies which used a direct immunoassay with the studies using RIA with extraction and chromatography revealed a significant difference. When an extraction and chromatography step was included, significantly lower differences in concentrations of total T were measured. Other studies have also reported the overestimation of concentrations by direct immunoassays ([@DMT038C88]; [@DMT038C38]). As data were grouped per assay method, the between-study heterogeneity in the subgroups was lower compared with the main analysis. The subgroup analysis performed for the free T assessment did not identify a significant difference between concentrations obtained using direct immunoassay versus the calculation method or equilibrium dialysis. The latter two methods are regarded to be a more reliable measure of free T concentrations ([@DMT038C8]; [@DMT038C85]; [@DMT038C70]), so this is an unexpected finding. This may be attributable to procedural differences, which, in the case of the calculation method or equilibrium dialysis apparently differ more widely between laboratories than the RIA method. Other sources for the variation can be explained by the variations in the study population, e.g. different age and body mass index (BMI) ranges. No adjustment could be made for these confounding factors.

This meta-analysis has limitations which should be considered. The included studies were not strong in design with regard to preventing selection bias and only a few studies used a double-blind or single-blind design. However, due to the within-subject comparison, this bias seems to be of little relevance. Incomplete outcome data (attrition bias) seemed to be one of the most important factors affecting the analyses as some reasons for early discontinuation could be related to low androgen levels. The search was performed using terms (MeSH) in the title or abstracts, and therefore some publications could have been missed. However, this problem was partly covered by performing a hand search on the reference lists of all selected papers. For consistency reasons, only studies investigating COCs with a 21:7 or 24:4 regimen were eligible for inclusion. Only two of the included studies evaluated the effects of a COC with a 24:4 regimen ([@DMT038C25]; [@DMT038C4], [@DMT038C5]). This COC containing E~2~ and nomegestrol acetate (NOMAC) was not included in the subgroup analyses, because it did not qualify for the subgroups. The effects of COCs with a continuous regimen were also not evaluated in the current meta-analysis. However, studies comparing COCs using a continuous regimen with COCs using the 21:7 regimen report that T and SHBG levels are affected to the same extent ([@DMT038C61]; [@DMT038C91]). This shows that the maximal effect of a COC on T and SHBG is already reached within 3 weeks of use.

Based on the outcome of this review, it seems reasonable to conclude that the suppression of T is caused by all three mechanisms of action mentioned in the introduction of this paper, i.e. suppression of both ovarian and adrenal androgen synthesis, along with increased SHBG levels. The average decrease of total T was 31% and for free T it was 61%, which cannot solely be explained by direct inhibition of ovarian androgen synthesis. Under normal conditions, ∼25% of T is produced by the ovaries, whereas the adrenals synthesize another 25% and the remaining 50% is derived from peripheral conversion ([@DMT038C65]; [@DMT038C8]; [@DMT038C16]). Thus, the other two mechanisms of action, the increase in SHBG increase and the inhibition of adrenal androgen synthesis, seem to be relevant too. Possibly the peripheral conversion of T from (pre)androgens is diminished due to lower levels of (pre)androgens. This contention is supported by the fact that many studies have also found decreased levels of dihydrotestosterone, AD, DHEA, DHEA-S and androstanediol glucuronide after COC use ([@DMT038C34]; [@DMT038C119]; [@DMT038C4], [@DMT038C5]). AD is the major source of peripheral T production ([@DMT038C65]; [@DMT038C16]). The lower levels of AD, DHEA and DHEA-S are possibly the result of suppression of the adrenal androgen synthesis ([@DMT038C18]; [@DMT038C54]; [@DMT038C21]).

This review also confirms that SHBG significantly increases during COC use, an effect which varied depending on the dose of the EE component. COCs with the second generation progestin combined with the lowest EE dose (20--25 µg) had the least effect on SHBG. A separate analysis between the monophasic COCs with a second or third generation progestin, both containing 30--35 µg EE, revealed that the third generation progestin had a stronger effect on SHBG. All data confirm that COCs containing a second generation progestin increase SHBG considerably less compared with all other progestins (∼50% versus 150--250% elevation). Since SHBG is the main carrier protein of T one would expect more T to be bound when the SHBG increases are higher ([@DMT038C7]; [@DMT038C108]; [@DMT038C119]; [@DMT038C4]). However, all progestin types reduce total and free T to the same extent and no significant difference in lowering T levels was found when comparing the 20--25 µg with the 30--35 µg EE dose except for a small but significant difference (P = 0.02) when the lower EE dose was combined with a first or second generation progestin. Similar results have been found in other studies ([@DMT038C51]; [@DMT038C47]; [@DMT038C15]; [@DMT038C91]). Apparently, the moderate SHBG increase caused by second generation progestins already exerts the maximal effect on additional binding of T and further lowering of free T levels.

Apart from estrogens and androgens, progestins can also bind to SHBG and albumin ([@DMT038C94]). Competition with T or E~2~ for SHBG might decrease the circulating concentration of the respective progestin in the circulation and, concomitantly, increase the free T and E~2~ levels, thereby indirectly influencing the SHBG synthesis, be it to an as yet undetermined extent.

As mentioned above, T deficiency is thought to be associated with a broad range of undesired effects including diminished well-being and quality of life, mood changes (depression, irritation, moodiness), loss of energy, cognitive disturbances, interference with optimal sexual function, declining muscle mass and strength and lowering of bone mass and bone density ([@DMT038C8]; [@DMT038C107]). The clinical consequences of the suppressed T levels during COC use have so far gained little attention. Only a few studies have combined the investigation of the effects of COCs on androgens with the occurrence of side effects which could be attributed to suppressed androgen levels. These studies report conflicting results ([@DMT038C11]; [@DMT038C92]; [@DMT038C35]; [@DMT038C37]; [@DMT038C103]; [@DMT038C19]; [@DMT038C12]; [@DMT038C27]; [@DMT038C80]). Although estrogens have been clearly identified as key hormones for maintaining bone mass ([@DMT038C78]; [@DMT038C84]; [@DMT038C77]), androgens are also important regulators of skeletal growth and maturation ([@DMT038C67]; [@DMT038C84]; [@DMT038C45]). Data on the effect of androgens in women are scarce but T may exert an effect on protein synthesis and increase muscle mass ([@DMT038C39]; [@DMT038C89]). Therefore, the negative effect of COCs on T levels may have some impact on bone mass and also on muscle strength.

In conclusion, the current systematic literature review and meta-analysis demonstrates that COCs decrease circulating levels of total T and free T and increase SHBG concentrations. Due to the SHBG increase, free T levels decrease twice as much as total T. The estrogen dose and progestin type of the COC do not influence the decline of total or free T, but both affect the magnitude of the effect on SHBG. The clinical implications of suppressed androgen levels during COC use remain to be elucidated. Further research investigating the COC\'s effects on androgens combined with their effects on other clinical outcomes is warranted.
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[^1]: 1, risk of bias assessment performed in relation to the effect measures used in the meta-analysis (scoring low, high or unclear risk, seven domains; see [Supplementary data, Table SI](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmt038/-/DC1) for assessment per study); 2, study has more treatment or study groups, but only data of group(s) fulfilling the selection criteria for inclusion in the meta-analyses have been used; 3, information derived from [@DMT038C51]; including free T results); 4, reported unit is µg/dl, but assumed this is ng/dl; 5, characteristics similar for all treatment groups due to crossover design; 6, total T results are not reported.

[^2]: AFTC, apparent free testosterone concentration; BMI, body mass index; CPA, cyproterone acetate; CV, coefficients of variation; DNG, dienogest; DRSP, drospirenone; DSG, desogestrel; E2, estradiol; E2 V, estradiol valerate; (E)CLIA, (electro)chemiluminescence immunoassay; EE, ethinyl estradiol; ELISA, enzyme-linked immunosorbent assay; GSD, gestodene; LLQ, lower limit of quantification; (L)NG, (levo)norgestrel; OC, oral contraceptive; *N*, number; NET(A), norethindrone (acetate); NGM, norgestimate; NOMAC, nomegestrol acetate; NR, not reported; RIA, radioimmunoassay; RSD, relative standard deviation; SD, standard deviation; SE, standard error; SHBG, sex hormone-binding globulin; T, testosterone; Tr., treatment.

[^3]: CI, confidence interval; COC, combined oral contraceptive; MD, mean difference; SHBG, sex hormone-binding globulin; T, testosterone.
